These results appear to compare favorably to historical expectations with doublet regimens in a similar older population, including with azacitidine + venetoclax, where the CRc rate was 67% and the 2-year OS in patients with FLT3-mutated AML was 20–40%. The gene discussed is FLT3; the disease is acute myeloid leukemia.